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ABSTRACT 
Background: To validate and further improve the stratification of intermediate risk prostate 
cancer into favorable and unfavorable subgroups for patients undergoing radical prostatectomy. 
Materials and Methods: The SEARCH database was queried for IR patients undergoing radical 
prostatectomy without adjuvant radiotherapy. UIR disease was defined any patient with at least 
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one unfavorable risk factor (URF), including primary Gleason pattern 4, 50% of more biopsy 
cores containing cancer, or multiple National Comprehensive Cancer Network IR factors. 
Results: 1586 patients with IR prostate cancer comprised the study cohort. Median follow-up 
was 62 months. Patients classified as UIR were significantly more likely to have pathologic high 
risk features , such as Gleason score 8-10, pT3-4 disease, or lymph node metastases, than FIR 
patients (p<0.001). Furthermore, UIR patients had significantly higher rates of PSA-relapse 
(PSA, hazard ratio (HR) =1.89, P<0.001) and distant metastasis (DM, HR =2.92, P=0.001), but 
no difference in prostate cancer-specific mortality (PCSM) or all-cause mortality in multivariable 
analysis. On secondary analysis, patients with ≥2 URF had significantly worse PSA-RFS, DM, 
and PCSM than those with 0 or 1 URF. Moreover, 40% of patients with ≥2 URF had high risk 
pathologic features. 
Conclusions: Patients with UIR prostate cancer are at increased risk of PSA relapse, DM, and 
pathologic upstaging following prostatectomy. However, increased risk of PCSM was only 
detected in those with ≥2 URF. This suggests that further refinement of the UIR subgroup may 
improve risk stratification. 
 
Introduction 
Prostate cancer is a clinically diverse entity comprising indolent tumors that can be safely 
observed,1,2 highly aggressive, treatment refractory tumors that produce lethal metastases,3,4 and 
a wide spectrum in between. In order to help distinguish between these possibilities and guide 
treatment recommendations, the National Comprehensive Cancer Network (NCCN) has 
developed a risk stratification system based on clinical tumor stage, biopsy Gleason, and 
pretreatment PSA.5 
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According to the NCCN system, patients with clinical tumor stage T2b-T2c, biopsy Gleason 
score 7, or a pretreatment PSA of 10 to 20 ng/mL, but without other high risk features, are 
classified as intermediate-risk (IR). However, significant biologic and clinical heterogeneity 
exists within the IR group,6,7 and optimal management of this group remains controversial.8 A 
proposed modification to the NCCN system subdivides IR into favorable (FIR) and unfavorable 
(UIR) subgroups based on the primary Gleason pattern, percentage of positive prostate biopsy 
cores, and the number of NCCN intermediate-risk factors.6 The prognostic significance of these 
subgroups for patients undergoing radiation therapy has been validated in multiple independent 
datasets.9-11 
It has been suggested that the relatively worse outcomes for men with UIR prostate cancer are 
largely attributable to these patients having an increased risk of harboring occult high grade 
disease undetected by biopsy or more advanced tumor stage than appreciated clinically on digital 
rectal exam.12 However, the risk of pathologic upstaging for FIR versus UIR has not been 
reported to date, and the applicability of these classifications to patients undergoing 
prostatectomy is unknown. Additionally, a limitation of the current proposed definition of the 
UIR subgroup is that it is still a relatively broad classification encompassing approximately 60% 
of all IR patients.6,9 Thus, it is likely that significant heterogeneity exists even within those 
classified as UIR, and further stratification of this group is desirable. For these reasons, we 
analyzed a large cohort of men with IR prostate cancer undergoing radical prostatectomy across 
multiple medical centers in order to validate the FIR and UIR prostate cancer definitions in a 
surgical population, assess the risk of pathologic upstaging at time of surgery for each group, and 
more precisely define which UIR patients are at highest risk of distant metastasis (DM) and 
prostate cancer-specific mortality (PCSM) following radical prostatectomy. 
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Methods 
Design and Participants 
After obtaining Institutional Review Board approval, patients undergoing radical prostatectomy 
from 1988 to 2013 at six Veterans Affairs Medical Centers (San Diego, West Los Angeles, and 
Palo Alto, CA; Durham and Asheville, NC, and Augusta, Georgia) were entered into the 
SEARCH database.13 Patients who received neoadjuvant therapy were excluded. 
Intermediate-risk prostate cancer was defined according to NCCN guidelines as patients with 
clinical state T2b or T2c, biopsy Gleason of 7, or PSA 10-20ng/ml but without high-risk factors 
(PSA>20ng/ml, clinical stage T3a or higher, or biopsy Gleason>7).5 There were 2059 radical 
prostatectomy patients within the SEARCH database classified as NCCN intermediate-risk. 
Patients with missing outcome data (n=16), missing biopsy information (n=339), race (n=13), 
pathological data (n=41), or patients who received adjuvant radiation therapy (n=63) were 
excluded, leaving 1586 patients for analysis. 
NCCN IR patients were categorized into two mutually exclusive groups: UIR and FIR prostate 
cancer. UIR was defined as any IR patient with biopsy Gleason score 4+3, percentage of positive 
biopsy cores (PPBC) ≥50%, or multiple intermediate-risk factors (clinical state T2b or T2c, 
Biopsy Gleason of 7, or PSA 10-20ng/ml). All others were classified as FIR. 
PSA-RFS after RP was defined as a single PSA greater than 0.2 ng/ml, 2 values of 0.2 ng/ml, or 
secondary treatment for an elevated postoperative PSA.14 Development of distant metastases 
(DM) was determined radiographically as evidence of prostate cancer outside of the prostate, 
seminal vesicles, or pelvic lymph nodes. Prostate cancer-specific death (PCSM) was defined as 
metastatic progressive CRPC at time of death with no obvious indication of another cause of 
death. All-cause mortality (ACM) included death from any cause. 
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Statistical Analysis 
Baseline characteristics of UIR and FIR patients were compared using t-tests or rank sum tests 
for continuous variables and chi-squared tests for categorical variables. We tested the differences 
between number of UIR factors (0 vs. 1 vs. 2-3) and pathological disease characteristics using 
chi-squared tests. 
Cox proportional hazards were used to test the differences in time to PSA-RFS, DM, and ACM 
between UIR and FIR patients in both univariable and multivariable models (adjusted for clinical 
state ≤ T2a vs. T2b-T2c, pretreatment PSA <10 vs. 10-20ng/ml, age, race, and year of surgery). 
Comparisons of time to PCSM were analyzed using a competing-risk model with non-PCa death 
as the competing risk. We then repeated these analyses to test the associations between the 
number of UIR risk factors (0 vs. 1 vs. 2-3) and the outcomes listed above. Sensitivity analyses 
were conducted among patients with ≥8 biopsy cores. Cumulative incidence curves were used to 
display the results graphically and differences between groups were tested using the log-rank 
test. Statistical significance was defined as P<0.05. All analyses were performed using Stata 
v14.0. 
Results 
Patient demographics 
In our study cohort (n=1586), 961 (60.6%) patients were classified as UIR and 625 (39.4%) as 
FIR (Table 1). Median follow-up in the entire cohort was 62 months. In addition to 
characteristics used to define FIR and UIR (biopsy Gleason score, PPBC), UIR patients had 
significantly higher median pre-surgical PSA (7.6 vs. 6.2 ng/mL, p<0.001) and higher clinical 
stage (p<0.001). UIR patients also had significantly increased risk of pathologic upstaging at 
surgery, with higher rates of extracapsular extension (23.1% vs. 11.0%, p<0.001), seminal 
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vesicle invasion (13.1% vs. 4.2%, p<0.001), and pathologic Gleason score 8-10 (13.3% vs. 6.4%, 
P<0.001). UIR patients were also somewhat more likely to have positive margins (42.3% vs. 
37.1%, p=0.042). Although pelvic lymph node dissection (PLND) was more likely to be 
performed for UIR patients, there was no significant difference in the rate of lymph node 
positivity in patients undergoing PLND (2.1% vs. 0.9%, P=0.194 by Fisher’s exact test). In total, 
31% of UIR patients had high risk pathologic features such as Gleason score 8-10, extracapsular 
extension, seminal vesicle invasion, or lymph node involvement present, compared to 15% of 
FIR patients. There was no significant difference between the UIR and FIR subgroups with 
respect to follow-up time, age, race, or year of surgery (all p-values >0.05). 
Clinical outcomes of UIR vs. FIR 
In univariable analysis (Table 2), UIR was associated with increased risk of PSA relapse 
(HR=1.89, P<0.001) and DM (HR=2.92, P=0.001). There was a trend towards worse PCSM with 
UIR disease, but this did not reach statistical significance (HR=2.27, P=0.057). After adjusting 
for other covariates in multivariable analysis (Table 2), PSA-RFS (HR=1.85, P<0.001) and DM 
(HR = 2.95, P=0.001) remained significantly worse for UIR patients, but PCSM was not 
significantly different (HR=1.94, P=0.147). There was no association between UIR disease and 
ACM. The cumulative incidences of PSA relapse, DM, PCSM, and ACM in the FIR and UIR 
groups are shown in Figure 1. 
Risk of pathologic upstaging based on number of UIR factors 
Because in our cohort the UIR group comprised 60.6% of the total population, we chose to 
further stratify the UIR subgroup based on the total number of UIR factors present in each 
patient (Table 3). In our cohort, patients with 2-3 UIR factors were significantly more likely to 
have high risk features noted pathologically at surgery including Gleason score 8-10 (18.4%), 
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pathological stage T3-4 (40.2%), extracapsular extension (31.1%), and seminal vesicle invasion 
(18.7%) versus patients with 0 or 1 UIR factors (p≤0.001 for all comparisons). Patient with 2-3 
UIR were also significantly more likely to have positive margins (p=0.004). In total, 15%, 25%, 
and 41% of patients with 0, 1, and 2-3 UIR factors, respectively, had high risk pathologic 
features including Gleason score 8-10, extracapsular extension, seminal vesicle invasion, or 
lymph node involvement. Similarly, 7%, 15%, and 23% of these respective patients had very 
high risk pathologic features including primary Gleason pattern 5, seminal vesicle invasion, pT4 
stage, or lymph node involvement. 
Clinical outcomes based on number of UIR factors 
With zero UIR factors as the reference, patients having either 1 or 2-3 UIF factors were at 
increased risk of PSA-RFS (HRUIR=1= 1.57, P <0.001; HRUIR=2-3= 2.48, P<0.001) (table 4, Figure 
2). This result remained significant and little changed in multivariable analysis (HRUIR=1= 1.58, P 
<0.001; HRUIR=2-3= 2.42, P<0.001). However, only patients with 2-3 UIF factors had 
significantly increased risk of DM and PCSM in both univariable (HR=4.50, P<0.001; HR=4.13, 
P=0.001, respectively) and multivariable models (HR=4.85, P<0.001; HR=3.99, P=0.007, 
respectively) compared to patients with zero UIR factors. By contrast, patients with only 1 UIR 
factor had similar risk of DM and PCSM to those with zero UIR factors (P>0.05 for all 
comparisons). ACM was similar amongst all groups. 
Results among patients with ≥8 biopsy cores 
Given that the percentage of biopsy cores and primary Gleason pattern could be impacted by the 
total number of biopsy cores obtained, we performed a subgroup analysis only in those with ≥8 
biopsy cores (N=1340). Overall, results were similar to the entire cohort (Supplementary tables 1 
and 2). UIR was associated with increased risk of PSA relapse and DM in both univariable and 
Au
tho
r M
an
us
cri
pt
multivariable analyses, but not PCSM or ACM. Increasing numbers of UIR factors (0 vs. 1 vs. 2-
3) were associated with increased risk of PSA-RFS and DM in both univariable and 
multivariable analyses. However, only patients with 2-3 UIR factors had increased risk of 
PCSM. In multivariable analysis, the hazard ratios for DM (HR=9.96, P<0.001) and PCSM 
(HR=8.07, P=0.015) were even stronger in the subgroup of patients with at least 8 biopsy cores 
when comparing patients with 2-3 UIR to those with 0 UIR factors, although confidence 
intervals were wide. 
Discussion 
In this study, we confirmed that, similar to patients undergoing radiotherapy, patients treated 
with radical prostatectomy with UIR prostate cancer have worse PSA-RFS and DM compared to 
those with FIR disease. However, there was no significant difference in PCSM in multivariable 
analyses when comparing these subgroups, contrary to what has been reported previously in 
definitive radiotherapy series.6,9,10 This is may be attributable to the relatively short follow-up 
(63 months) for patients in our dataset, especially given the long natural history of IR prostate 
cancer. However, an alternative explanation is that salvage radiotherapy, administered nearly 
twice as frequently to patients with UIR prostate cancer as those with FIR disease in our cohort 
(27% vs. 15%, p<0.001), is efficacious in delaying or preventing subsequent PCSM for patients 
experiencing biochemical relapse following prostatectomy and helped mask differences in 
outcomes between these groups.15 In either case, we hypothesized that patients with multiple 
adverse risk factors may represent the proportion of UIR patients at highest risk of DM and 
PCSM. In fact, patients with 2 or more UIR factors had more than four times the risk of DM and 
of PCSM as patients with FIR prostate cancer, whereas patients with exactly 1 UIR factor had no 
significant difference in DM and PCSM as those with FIR disease. This suggests that significant 
Au
tho
r M
an
us
cri
pt
heterogeneity exists even within the UIR subgroup, and that the worse prognosis harbored by 
this group is primarily driven by those with multiple unfavorable risk factors. Moreover, our 
results suggest a single unfavorable risk factor in isolation may not significantly affect prognosis 
for those with IR disease. However, given the relatively short follow-up time of our study, 
further follow-up is required to support these conclusions. 
The risk of pathologic upstaging was substantial in our series for patients with UIR prostate 
cancer, with 31% of patients having high risk pathologic features such as Gleason score 8-10, 
extracapsular extension, seminal vesicle invasion, or lymph node involvement present. The risk 
of pathologic upstaging was even higher for patients with 2 or more UIR factors, with 41% 
having high risk features and 23% have primary Gleason pattern 5, pT3b-T4 disease, both 
considered NCCN very high risk factors,3 or lymph node positivity. Thus, many patients with 2 
or more UIR have occult high risk disease that may go undetected prior to surgery due to biopsy 
sampling error, the poor sensitivity of clinical staging via digital rectal exam, or both. Therefore, 
these patients may be candidates for clinical investigations studying additional presurgical 
evaluation to improve risk classification. For example, image-guided biopsy using a 
multiparametric MRI/TRUS fusion platform may represent a promising approach to ensure 
adequate sampling of prostate regions that are radiographically suspicious for high grade disease) 
or increase sampling of suspicious lesions areas often undersampled using standard TRUS-
guided biopsy, such as the anterior prostate.16-18 Additionally, preoperative MRI may increase 
detection of extracapsular extension and seminal vesicle invasion in comparison to digital rectal 
exam alone. However, although MRI has high specificity for extraprostatic extension, it has 
limited and variable sensitivity of approximately 60%.19 Further, the clinical utility of such 
approaches in terms of guiding therapeutic decisions is investigational at this point, and it 
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remains to be seen whether additional imaging modalities can improve risk stratification, and 
more importantly, improve the ability of a physician to make therapeutic recommendations 
beyond the standard clinical variables utilized in the our study. 
It should be noted that increasing number of UIR factors was associated with increased risk of 
surgical margin involvement, with positive margins seen 37%, 39%, and 48% of patients with 0, 
1, and 2 or more UIR factors, respectively (p=0.004). Therefore, we can’t completely rule out the 
possibility that these differences in surgical margin status could have impacted our results, in 
addition to other clinicopathologic factors. However, we think that the differences in margin 
status are more likely to be a result of the higher risk of extraprostatic extension observed in 
patients with multiple UIR factors, rather than differences in surgical quality between these 
subgroups. Further, a recent large, multi-institutional study found that although positive surgical 
margins increased the risk of biochemical recurrence, there was no association with PCSM,20 
making it unlikely that the increased risk of DM and PCSM noted in those with 2 or more UIR 
factors was related in any way to margin status. It is also notable that the surgical margin 
positivity rate in our study was somewhat higher than has been reported in some other series.20,21 
This could be attributable to differences in surgical technique, surgeon experience, pathologic 
margin evaluation procedures, baseline risk of extraprostatic extension in the respective cohorts, 
or other factors. 
Our results validate in surgical patients the favorable versus unfavorable classifications of 
intermediate-risk prostate cancer that have been proposed previously for patients undergoing 
radiotherapy.6,8-11 However, this study also has several unique aspects and strengths that extend 
these prior findings. This study is the first to our knowledge to demonstrate increased risk of 
pathologic upstaging with UIR prostate cancer in comparison to FIR. Further, because this is a 
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surgical population that did not receive neoadjuvant androgen deprivation, our study avoids one 
of the major confounding variables that limited conclusions in previous studies from 
radiotherapy cohorts with intermediate-risk disease. Additionally, our data demonstrate that there 
is heterogeneity even within the UIR group based on the number of UIR factors present, and that 
only patients with two or more UIR factor have worse PCSM than FIR patients. Another unique 
aspect of our study was the inclusion of a much higher proportion of African American patients 
(42%) than previous studies of FIR and UIR prostate cancer. Although differences in biology,22 
pathologic upstaging,23 and clinical outcomes have been described for prostate cancers 
developing in African Americans,24,25 our data provide confirmation that the FIR and UIR 
classifications are relevant in this population as well. 
Several weaknesses of this study warrant further discussion. First, this is a retrospective study, 
with all attendant biases that accompany such investigations. Additionally, the median follow-up 
of our series is relatively short for outcomes such as DM and PCSM given the long natural 
history of intermediate-risk prostate cancer, and late occurring DM and PCSM events could 
affect the results with increased follow-up. Also, we also were not able to control for imbalances 
in the administration of salvage therapies such as radiation or androgen deprivation therapy 
given the complexity of such analyses,26 and we can’t rule out the possibility that differences in 
salvage therapy administration impacted the outcomes observed. Additionally, other factors not 
analyzed in our study, such as the percentage of Gleason pattern 4,27 nuclear morphology,28 
ductal histology,29 and tertiary Gleason pattern 5,30 could also be important prognostic factors to 
consider for intermediate risk patients. Nomogram-based risk stratification, which was not 
analyzed in this study, may provide even more accurate risk prediction than categorical systems 
such as ours, given their continuous nature. Lastly, given that our study cohort was entirely 
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treated within the VA Medical System, we can’t be certain that these results are applicable to 
other populations treated in other medical settings, such as tertiary care academic centers or 
private community hospitals. Nevertheless, our study represents to our knowledge the largest 
investigation of clinical heterogeneity amongst intermediate-risk prostate cancer patients 
undergoing radical prostatectomy to date, and both supports and supplements results from prior 
studies in this population.6,9,10 
In conclusion, our study validates that patients with UIR prostate cancer have increased risk of 
PSA relapse and DM in comparison to FIR patients following radical prostatectomy, which is 
likely at least in part due to their increased risk of harboring clinically undetected pathologic 
high grade disease or extraprostatic extension. Furthermore, patients with 2 or more UIR factors 
have increased risk and PCSM in comparison to patients with 0 or 1 UIR factor, even with short-
term follow-up. By contrast, patients with FIR and 1 UIR have similar rates of DM and PCSM, 
implying that the relatively poorer prognosis of UIR patients is driven by patients with multiple 
UIR factors. Recognition of the heterogeneity in clinical outcomes amongst the intermediate-risk 
population will hopefully aid in personalizing treatment recommendations for these patients. 
 
References 
 1. Klotz L, Vesprini D, Sethukavalan P, et al: Long-term follow-up of a large active 
surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272-7, 2015 
 2. Wilt TJ, Brawer MK, Jones KM, et al: Radical prostatectomy versus observation 
for localized prostate cancer. N Engl J Med 367:203-13, 2012 
 3. Sundi D, Wang VM, Pierorazio PM, et al: Very-high-risk localized prostate 
cancer: definition and outcomes. Prostate Cancer Prostatic Dis 17:57-63, 2014 
Au
tho
r M
an
us
cri
pt
4. Beltran H, Tomlins S, Aparicio A, et al: Aggressive variants of castration-resistant 
prostate cancer. Clin Cancer Res 20:2846-50, 2014 
 5. Mohler JL, Kantoff PW, Armstrong AJ, et al: Prostate cancer, version 2.2014. J 
Natl Compr Canc Netw 12:686-718, 2014 
 6. Zumsteg ZS, Spratt DE, Pei I, et al: A new risk classification system for 
therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-
escalated external-beam radiation therapy. Eur Urol 64:895-902, 2013 
 7. Cancer Genome Atlas Research N: The Molecular Taxonomy of Primary Prostate 
Cancer. Cell 163:1011-25, 2015 
 8. Zumsteg ZS, Zelefsky MJ: Short-term androgen deprivation therapy for patients 
with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of 
care? Lancet Oncol 13:e259-69, 2012 
 9. Keane FK, Chen MH, Zhang D, et al: The likelihood of death from prostate 
cancer in men with favorable or unfavorable intermediate-risk disease. Cancer 120:1787-93, 
2014 
 10. Keane FK, Chen MH, Zhang D, et al: Androgen deprivation therapy and the risk 
of death from prostate cancer among men with favorable or unfavorable intermediate-risk 
disease. Cancer 121:2713-9, 2015 
 11. Raldow AC, Zhang D, Chen MH, et al: Risk Group and Death From Prostate 
Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate 
Cancer. JAMA Oncol 1:334-40, 2015 
 12. D'Amico AV: Personalizing the management of men with intermediate-risk 
prostate cancer. Eur Urol 64:903-4, 2013 
Au
tho
r M
an
us
cri
pt
13. Moreira DM, Howard LE, Sourbeer KN, et al: Predicting bone scan positivity in non-
metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 18:333-7, 2015 
 14. Freedland SJ, Sutter ME, Dorey F, et al: Defining the ideal cutpoint for 
determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 
61:365-9, 2003 
 15. Stephenson AJ, Scardino PT, Kattan MW, et al: Predicting the outcome of 
salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 
25:2035-41, 2007 
 16. Schoots IG, Roobol MJ, Nieboer D, et al: Magnetic resonance imaging-targeted 
biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to 
standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol 
68:438-50, 2015 
 17. Siddiqui MM, Rais-Bahrami S, Truong H, et al: Magnetic resonance 
imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-
core transrectal ultrasound biopsy. Eur Urol 64:713-9, 2013 
 18. Volkin D, Turkbey B, Hoang AN, et al: Multiparametric magnetic resonance 
imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the 
detection of anteriorly located prostate cancers. BJU Int 114:E43-9, 2014 
 19. de Rooij M, Hamoen EH, Witjes JA, et al: Accuracy of Magnetic Resonance 
Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. Eur Urol, 2015 
 20. Stephenson AJ, Eggener SE, Hernandez AV, et al: Do margins matter? The 
influence of positive surgical margins on prostate cancer-specific mortality. Eur Urol 65:675-80, 
2014 
Au
tho
r M
an
us
cri
pt
21. Yossepowitch O, Briganti A, Eastham JA, et al: Positive surgical margins after radical 
prostatectomy: a systematic review and contemporary update. Eur Urol 65:303-13, 2014 
 22. Yamoah K, Johnson MH, Choeurng V, et al: Novel Biomarker Signature That 
May Predict Aggressive Disease in African American Men With Prostate Cancer. J Clin Oncol 
33:2789-96, 2015 
 23. Sundi D, Ross AE, Humphreys EB, et al: African American men with very low-
risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should 
active surveillance still be an option for them? J Clin Oncol 31:2991-7, 2013 
 24. Faisal FA, Sundi D, Cooper JL, et al: Racial disparities in oncologic outcomes 
after radical prostatectomy: long-term follow-up. Urology 84:1434-41, 2014 
 25. Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate 
cancer mortality. Cancer 118:4280-9, 2012 
 26. Kennedy EH, Taylor JM, Schaubel DE, et al: The effect of salvage therapy on 
survival in a longitudinal study with treatment by indication. Stat Med 29:2569-80, 2010 
 27. Cole AI, Morgan TM, Spratt DE, et al: Prognostic Value of Percent Gleason 
Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. J Urol 
196:405-11, 2016 
 28. Veltri RW, Isharwal S, Miller MC, et al: Nuclear roundness variance predicts 
prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years 
of follow-up after radical prostatectomy. Prostate 70:1333-9, 2010 
 29. Seipel AH, Delahunt B, Samaratunga H, et al: Ductal adenocarcinoma of the 
prostate: histogenesis, biology and clinicopathological features. Pathology 48:398-405, 2016 
 30. Patel AA, Chen MH, Renshaw AA, et al: PSA failure following definitive treatment of 
prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 298:1533-8, 2007 
Au
tho
r M
an
us
cri
pt
Figure Legends: 
Figure 1. Cumulative incidence of PSA relapse (A), distant metastasis (B), prostate cancer 
specific mortality (C), and all-cause mortality (D) in favorable intermediate risk (FIR) and 
unfavorable intermediate risk prostate cancer patients from time of radical prostatectomy. 
Figure 2. Cumulative incidence of PSA relapse (A), distant metastasis (B), prostate cancer 
specific mortality (C), and all-cause mortality (D) in patients with 0, 1, or 2-3 unfavorable 
intermediate risk (UIR) factors. UIR factors are defined as Gleason score 4+3, ≥50% positive 
biopsy cores, or more than one NCCN intermediate risk factor. 
 
Table 1. Baseline clinical and pathological characteristics (N=1586) 
 
  Favorable Unfavorable P value 
No. of Patient (%) 625 (39.4) 961 (60.6) - 
PSA Follow-up mo, Median (IQR)* 50.6 (26.2, 96.5) 41.0 (21.3, 82.0) 0.0021 
Total Follow-up mo, Median (IQR)** 63.5 (34.2, 115.2) 61.4 (31.1, 110.1) 0.2471 
Age, yr, Mean (SD) 62.1 (6.1) 61.9 (6.2) 0.4592 
Race   0.6793 
White 344 (55.0) 527 (54.9)  
Black 265 (42.4) 402 (41.8)  
Other 16 (2.6) 32 (3.3)  
Year of Surgery, Median (IQR) 2008 (2003, 2012) 2008 (2003, 2012) 0.3221 
Clinical T Stage, No. (%)   <0.0014 
 T1a-c 409 (65.4) 505 (52.6)  
 T2 20 (3.2) 26 (2.7)  
 T2a 156 (25.0) 242 (25.2)  
 T2b 40 (6.4) 104 (10.8)  
 T2c 0 84 (8.7)  
Biopsy Gleason Score (%)   <0.0014 
 ≤6 201 (32.2) 107 (11.1)  
 3+4 424 (67.8) 459 (47.8)  
 4+3 0 395 (41.1)  
PSA, Median (IQR) 6.2 (4.9, 10.0) 7.6 (5.2, 11.3) <0.0011 
Percentage Positive Biopsy Cores 
Median (IQR) 
  <0.0014 
 <50% 625 (100)  369 (38.4)  
Au
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≥50% 0 592 (61.6)  
Pathological Gleason Score (%)   <0.0013 
 ≤6 181 (29.0) 125 (13.0)  
 3+4 306 (49.0) 457 (47.6)  
 4+3 98 (15.6) 251 (26.1)  
 8-10 40 (6.4) 128 (13.3)  
Pathological Stage (%)   <0.0013 
T0-T2 534 (85.4) 663 (69.0)  
T3 76 (12.2) 264 (27.5)  
T4 15 (2.4) 34 (3.5)  
Positive Surgical Margins (%) 232 (37.1) 406 (42.3) 0.0423 
Extracapsular Extension (%) 69 (11.0) 222 (23.1) <0.0013 
Seminar Vesicle Invasion (%) 26 (4.2) 126 (13.1) <0.0013 
Lymph Nodes (%)   <0.0014 
No 410 (65.6) 749 (77.9)  
Yes 5 (0.8) 19 (2.0)  
Not Done 210 (33.6) 193 (20.1)  
Number of Lymph Nodes Removed 
Median (IQR) 
4 (2, 8) 5 (2, 10) 0.0091 
Received Salvage ADT (%) 54 (8.6) 189 (19.7) <0.0013 
Received Salvage XRT (%) 96 (15.4) 257 (26.7) <0.0013 
 
Abbreviations: SD, standard deviation; ADT, androgen-deprivation therapy; PSA, prostate-specific antigen; XRT, 
radiation therapy 
P-value calculated using 1rank sum test 2student t test 3chi-squared test4Fisher’s exact test 
*Reported among those who did not recur 
**Reported among those who did not die 
 
 
Table 2. Association between favorable vs. unfavorable intermediate-risk and prostate cancer outcomes 
 
 Univariable  Multivariable* 
 HR (95% CI) p-value HR (95% CI) p-value 
PSA-RFS     
 UIR vs FIR 1.89 (1.58, 2.26) <0.001 1.85 (1.54, 2.23) <0.001 
DM     
 UIR vs FIR 2.92 (1.55, 5.47) 0.001 2.95 (1.55, 5.63) 0.001 
PCSM     
 UIR vs FIR 2.27 (0.97, 5.27) 0.057 1.94 (0.79, 4.76) 0.147 
ACM     
 UIR vs FIR 1.08 (0.86, 1.36) 0.522 1.07 (0.84, 1.37) 0.581 
 
*Adjusted for: clinical tumor stage (≤T2a vs. T2b-T2c), pretreatment PSA (<10 vs. 10-20), age, race, year of surgery 
and center. 
Abbreviation: PSA-RFS: Prostate-specific antigen recurrence-free survival; DM: distant metastasis; PCSM: prostate 
cancer specific mortality; ACM: all-cause mortality 
** Note: Out of 1586 patients, there were 567 recurrences, 63 distant metastases, 30 death of prostate cancer and 
299 all-cause deaths 
Table 3. Risk of pathologic upstaging stratified by number unfavorable intermediate-risk factors 
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  Favorable Unfavorable P value 
 0 UIR factors 1 UIR factor 2 or 3 UIR factors  
No. of Patient (%) 625 (39.4) 598 (37.7) 363 (22.9)  
Pathological Gleason Score (%)    <0.0011 
≤6 181 (29.0) 96 (16.0) 29 (8.0)  
3+4 306 (48.9) 309 (51.7) 148 (40.8)  
4+3 98 (15.7) 132 (22.1) 119 (32.8)  
8-10 40 (6.4) 61 (10.2) 67 (18.4)  
Pathological Stage (%)    <0.0011 
 T2 534 (85.4) 446 (74.6) 217 (59.8)  
 T3 76 (12.2) 129 (21.6) 135 (37.2)  
 T4 15 (2.4) 23 (3.8) 11 (3.0)  
Positive Surgical Margins (%) 232 (37.1) 233 (39.0) 173 (47.7) 0.0041 
Extracapsular Extension (%) 69 (11.0) 109 (18.2) 113 (31.1) <0.0011 
Seminar Vesicle Invasion (%) 26 (4.2) 58 (9.7) 68 (18.7) <0.0011 
Lymph Nodes (%)    <0.0012 
No 410 (65.6) 436 (72.9) 313 (86.2)  
Yes 5 (0.8) 7 (1.2) 12 (3.3)  
Not Done 210 (33.6) 155 (25.9) 38 (10.5)  
 
1P-value calculated using chi-squared test 2Fisher’s exact test 
 
 
Table 4. Association between number of UIR factors and prostate cancer outcomes  
 
 Univariable  Multivariable* 
 HR (95% CI) p-value HR (95% CI) p-value 
PSA-RFS 
    
0 UIR risk factors Ref.  Ref.  
1 UIR risk factor 1.57 (1.28, 1.92) <0.001 1.58 (1.29, 1.94) <0.001 
2-3 UIR risk factors 2.48 (2.02, 3.06) <0.001 2.42 (1.94, 3.03) <0.001 
DM     
0 UIR risk factors Ref.  Ref.  
1 UIR risk factor 1.89 (0.92, 3.86) 0.082 1.98 (0.96, 4.09) 0.065 
2-3 UIR risk factors 4.50 (2.31, 8.77) <0.001 4.85 (2.39, 9.85) <0.001 
PCSM     
0 UIR risk factors Ref.  Ref.  
1 UIR risk factor 1.00 (0.33, 2.96) 0.993 0.91 (0.30, 2.75) 0.868 
2-3 UIR risk factors 4.13 (1.72, 9.90) 0.001 3.99 (1.46, 10.88) 0.007 
ACM     
0 UIR risk factors Ref.  Ref.  
1 UIR risk factor 1.01 (0.78, 1.32) 0.934 1.05 (0.80, 1.38) 0.719 
2-3 UIR risk factors 1.18 (0.89, 1.57) 0.256 1.11 (0.81, 1.51) 0.527 
 
*Adjusted for: clinical tumor stage (≤T2a vs. T2b-T2c), pretreatment PSA (<10 vs. 10-20), age, race, year of surgery 
and center. 
Abbreviation: PSA-RFS: Prostate-specific antigen recurrence-free survival; DM: distant metastasis; PCSM: prostate 
cancer specific mortality; ACM: all-cause mortality 
** Note: Out of 1586 patients, there were 567 recurrences, 63 distant metastases, 30 death of prostate cancer and 
299 all-cause deaths 
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